A definitive diagnosis of MADD is established through the identification of elevated levels of several acylcarnitine species in blood, along with increased excretion of multiple organic acids in urine, and through the detection of biallelic pathogenic variants in the ETFA, ETFB, or ETFDH genes. The gene discussed is ETFA; the disease is multiple acyl-CoA dehydrogenase deficiency.